Ads
related to: jak inhibitor drugs fda approved- Clinical Studies
View Clinical Trial Info For A
Rheumatoid Arthritis Treatment.
- Efficacy And Safety Data
View Efficacy & Safety Data For An
RA Treatment. HCP Site.
- Patient Support
View Patient Support Info For A
Rheumatoid Arthritis Treatment.
- Access Information
View Access & Coverage Info For A
Rheumatoid Arthritis Treatment.
- Physician Resources
Download HCP Resources For An
RA Treatment Option. HCP Site.
- Safety Profile
View The Safety Profile For
An RA Treatment. HCP Site.
- Clinical Studies
Search results
Results From The WOW.Com Content Network
A Janus kinase inhibitor, also known as JAK inhibitor or jakinib, [1] is a type of immune modulating medication, which inhibits the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway in lymphocytes.
In May 2018, the FDA approved tofacitinib citrate "for the treatment of adult patients in the U.S. with moderately to severely active ulcerative colitis." [22] Tofacitinib citrate is the first oral JAK inhibitor approved for use in chronic ulcerative colitis.
Currently, much attention is focused on developing Janus kinase inhibitors as drugs for immune diseases including inflammatory bowel diseases, rheumatoid arthritis, alopecia areata, and psoriases. [12] The first JAK inhibitor approved for the treatment of rheumatoid arthritis was tofacitinib. It has also shown promising results in other ...
The FDA approved AbbVie Inc's (NYSE: ABBV) Rinvoq (upadacitinib; 15 mg) for active psoriatic arthritis (PsA). Like Pfizer Inc's (NYSE: PFE) approval for Xeljanz, Rinvoq's approval also covers ...
Ruxolitinib (sold under the brand names Jakafi and Jakavi among others, and as Opzelura in cream form) is a medication used for the treatment of intermediate or high-risk myelofibrosis, [6] a type of myeloproliferative neoplasm that affects the bone marrow; [11] [12] polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea; [6] [13] and steroid-refractory ...
The FDA will not meet its action dates for AbbVie's (ABBV) sNDA for JAK inhibitor drug, Rinvoq (upadacitinib), for moderate to severe atopic dermatitis.
Ads
related to: jak inhibitor drugs fda approved